Premium
Cyclophosphamide, methotrexate, and 5‐fluorouracil in the treatment of metastatic prostate cancer. A southwest oncology group study
Author(s) -
Wozniak Antoinette J.,
Blumenstein Brent A.,
Crawford E. David,
Boileau Michael,
Rivkin Saul E.,
Fletcher William S.
Publication year - 1993
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19930615)71:12<3975::aid-cncr2820711229>3.0.co;2-d
Subject(s) - medicine , cyclophosphamide , methotrexate , fluorouracil , prostate cancer , cancer , oncology , chemotherapy , toxicity , refractory (planetary science) , prostate , surgery , gastroenterology , physics , astrobiology
Background . Hormone‐refractory metastatic prostate cancer remains a therapeutic challenge. Cyclophosphamide, methotrexate, and 5‐fluorouracil (CMF), a drug combination that is active in solid tumors, was evaluated using specific response criteria. Methods . Fifty‐two eligible patients with measurable (19), evaluable (29), or bone scan only (4) metastatic prostate cancer were treated with cyclophosphamide, 100 mg/m 2 every day by mouth, methotrexate, 15 mg/m 2 intravenously weekly, and 5‐fluorouracil, 300 mg/m 2 intravenously weekly. Treatment was given continuously unless interrupted by toxicity or disease progression. Results . There were two partial responses (7%) among the evaluable patients. Six (32%) measurable patients and four (14%) evaluable patients had stable disease. Median time to progression was 3.2 months for measurable and 2.8 months for evaluable disease patients. Median survivals were 10.9 and 10.2 months, respectively. There was no difference between the two groups with regard to response rate or survival. Toxicity was acceptable and consisted primarily of myelosuppression. Conclusions . CMF is minimally active in hormonerefractory metastatic prostate cancer.